Caribou Biosciences (Caribou Biosciences) Cash Flow for Lease Financing : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences Cash Flow for Lease Financing?

Caribou Biosciences's Cash Flow for Lease Financing for the three months ended in Dec. 2023 was $0.00 Mil. Caribou Biosciences's Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2023 ), Caribou Biosciences's Cash Flow for Lease Financing remained the same in Dec. 2023 ($0.00 Mil).

Caribou Biosciences Cash Flow for Lease Financing Historical Data

The historical data trend for Caribou Biosciences's Cash Flow for Lease Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caribou Biosciences Cash Flow for Lease Financing Chart

Caribou Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash Flow for Lease Financing

Caribou Biosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash Flow for Lease Financing	Get a 7-Day Free Trial												-	-	-	-	-

Caribou Biosciences Cash Flow for Lease Financing Calculation

Cash Flow for Lease Financing is change in cash flow resulting from increase or decrease in lease financing.

Cash Flow for Lease Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Caribou Biosciences Cash Flow for Lease Financing Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's Cash Flow for Lease Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

Caribou Biosciences (Caribou Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » Cash Flow for Lease Financing

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 7th Street, Suite 105, Berkeley, CA, USA, 94710

Website

https://www.cariboubio.com

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Executives

Syed Ali-aamir Rizvi	officer: Chief Medical Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner	officer: See Remarks	CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson	director	C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Barbara G Mcclung	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan	officer: Chief Business Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Dara Richardson-heron	director	C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Rachel E. Haurwitz	director, officer: See Remarks	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Andrew Guggenhime	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710